Knowledge, awareness, feasibility, and

debby-jeon
Published  · 23 slides · 0 views
↓ Download
Knowledge, awareness, feasibility, and
1 / 1
Knowledge, awareness, feasibility, and - slide 1 of 23 Knowledge, awareness, feasibility, and - slide 2 of 23 Knowledge, awareness, feasibility, and - slide 3 of 23 Knowledge, awareness, feasibility, and - slide 4 of 23 Knowledge, awareness, feasibility, and - slide 5 of 23 Knowledge, awareness, feasibility, and - slide 6 of 23 Knowledge, awareness, feasibility, and - slide 7 of 23 Knowledge, awareness, feasibility, and - slide 8 of 23 Knowledge, awareness, feasibility, and - slide 9 of 23 Knowledge, awareness, feasibility, and - slide 10 of 23 Knowledge, awareness, feasibility, and - slide 11 of 23 Knowledge, awareness, feasibility, and - slide 12 of 23 Knowledge, awareness, feasibility, and - slide 13 of 23 Knowledge, awareness, feasibility, and - slide 14 of 23 Knowledge, awareness, feasibility, and - slide 15 of 23 Knowledge, awareness, feasibility, and - slide 16 of 23 Knowledge, awareness, feasibility, and - slide 17 of 23 Knowledge, awareness, feasibility, and - slide 18 of 23 Knowledge, awareness, feasibility, and - slide 19 of 23 Knowledge, awareness, feasibility, and - slide 20 of 23 Knowledge, awareness, feasibility, and - slide 21 of 23 Knowledge, awareness, feasibility, and - slide 22 of 23 Knowledge, awareness, feasibility, and - slide 23 of 23
Description
Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial. Welcome to the prevention choice agenda! Elijah Kakande, Infectious Diseases

Related Topics

Download this presentation From Below

"Knowledge, awareness, feasibility, and" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

01
Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention: results from the SEARCH Dynamic Choice HIV prevention trial. Welcome to the prevention choice agenda! Elijah Kakande, Infectious Diseases Research Collaboration, SEARCH consortium No financial relationships to disclose.<br>
02
Main Question:
What is the Knowledge, awareness, feasibility, and acceptability of long-acting Cabotegravir for HIV prevention in SEARCH dynamic choice HIV prevention study?

Findings:
Knowledge of CAB-LA was very low at baseline
Awareness of CAB-LA increased during follow-up
CAB-LA was highly feasible and acceptable to deliver with high levels of satisfaction among men and women, and Youth and adults

Why it is important:
Delivery of CAB-LA to persons who need it most will require person-centered choice models and wider access to CAB-LA. Summary<br>
03
Background Injectable Cabotegravir (CAB-LA) is highly effective for HIV prevention1,2
The 48-week SEARCH Dynamic Choice HIV prevention study evaluated an intervention offering choice of CAB-LA, oral PrEP, or PEP3 (N=984):
53% of women and 72% of men were eligible, chose and received CAB-LA at study start.
Biomedical prevention coverage was 5-fold higher in the intervention vs SOC
New HIV infections were reduced to 0 in the intervention vs. 1.8% in SOC
Real-world implementation studies among men and women in Africa are lacking
This analysis: We evaluated the knowledge, awareness, feasibility, and acceptability of CAB-LA as a biomedical product in the SEARCH Dynamic Choice HIV Prevention trial. 1. Delany-Moretlwe S et al Lancet HIV, 2022; 2. Landovitz JR et al, NEJM 2021; 3. Kamya et al, CROI 2024<br>